Support line (toll-free) (844) 835-4325 | Events help (608) 828-8852 | Community

Free To Breathe - A Partnership For Lung Cancer Survival

participant Login

News

Featured Clinical Trial of the Week: Targeting Small Cell Lung Cancer with Anti-Depressant Drugs

  • October 25 2013

    Share |
    Featured Clinical Trial of the Week: Targeting Small Cell Lung Cancer with Anti-Depressant Drugs

    Researchers have found that the anti-depressant drugs imipramine (Tofranil®) and promethazine (Phenrgan®) can be used to kill small cell lung cancer cells in animal studies. While other new therapies often target only one of the chemical messengers within a cancer cell, these drugs target several different messengers at once, raising scientists' hopes that these drugs will make it more difficult for tumors to develop drug resistance.

    This clinical trial tests a drug similar to imipramine and promethazine, called desipramine (Norpramin®), to determine its effectiveness in patients with small cell lung cancer.

    Eligibility
    Patients with metastatic small cell lung cancer who have received at least one previous regimen of chemotherapy are eligible for this clinical trial.

    Visit ClinicalTrials.gov for more information on this trial.

    If you’re looking for further information on this and/or other lung cancer clinical trials, please contact our Clinical Trials Matching Service, where trained representatives will match your particular cancer and health issues to clinical trials that are available for you.

    0 comments

Leave a comment

Comment Guidelines

Basic HTML formatting permitted -
<ul>, <li>, <strong>, <em>, <a href>, <blockquote>, <code>

©2017 Free To Breathe | Lung Cancer Research Foundation | Federal Tax ID #14-1935776 | LCRF is a 501(c)(3) public charity.